APLM News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AP

Mkt Cap

$61.5M

Volume

6.23K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Apollomics, Inc. Company Operational Continuity UpdateApollomics Inc. reversed its wind-up plans after receiving $4.1 million in PIPE investments, appointed a new board and management team, and remains committed to continuing its global clinical trials for APL-101 (vebreltinib), a targeted oncology therapy.GlobeNewswire Inc. · Oct 14, 2025

Nasdaq Halts Apollomics Inc., Ltd.Nasdaq Stock Market halted trading for Apollomics Inc. on September 17, 2025, at 14:37:17 Eastern Time, requesting additional information from the company.GlobeNewswire Inc. · Sep 17, 2025

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid LeukemiaApollomics announced that its Phase 3 bridging trial of uproleselan in China for relapsed or refractory acute myeloid leukemia did not demonstrate a favorable benefit, with the median overall survival being lower in the uproleselan arm compared to the chemotherapy-only arm.GlobeNewswire Inc. · Dec 20, 2024

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressApollomics reported progress in its vebreltinib program, including new data in non-CNS MET fusion tumors and NSCLC with MET amplification. The company also announced the closure of its uproleselan program due to negative Phase 3 results from its licensor, GlycoMimetics.GlobeNewswire Inc. · Aug 14, 2024

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerFOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.GlobeNewswire Inc. · Mar 4, 2024

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price RequirementGlobeNewswire Inc. · Jan 19, 2024

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceFOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference on Thursday, January 18, 2024 at 11:00 a.m. ET.GlobeNewswire Inc. · Jan 17, 2024

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaFOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of enrollment in its Phase 3 bridging study evaluating uproleselan (APL-106), an investigational, first-in-class E-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia (relapsed/refractory AML).GlobeNewswire Inc. · Jan 3, 2024

Apollomics to Present at the 2024 Biotech ShowcaseFOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on Monday, January 8, 2024 at 10:30 a.m. PT at the Hilton San Francisco Union Square in San Francisco, Calif.GlobeNewswire Inc. · Jan 2, 2024

Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving PremarketShares of Salesforce, Inc. (NYSE: CRM) shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 billion, according to Benzinga Pro. The company reported quarterly earnings of $2.11 per share, which beat analyst estimates of $2.06 per share. Salesforce shares gained 9.4% to $252.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Aditxt, Inc. (NASDAQ: ADTX) shares rose 126.1% to $7.80 in pre-market trading. Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 74.7% to $0.5987 in pre-market trading. Connexa Sports recently reported a decline in sales for the second quarter. Clearmind Medicine Inc. (NASDAQ: CMND) rose 50.1% to $6.08 in pre-market trading after surging 22% on Wednesday. Clearmind Medicine recently announced results from its weight loss and metabolic disorder program. Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) shares surged 37.7% to $2.70 in pre-market trading after gaining over 3% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares ...Benzinga · Nov 30, 2023

AP

APLMApollomics Inc. Class A Ordinary Shares

APLM

Pay with—

Available Balance0.00

Your PositionYou don't own any APLM yet.

Related Tickers

Earnings